Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave's Q2 Revenues Increase 17 Percent As Losses Narrow

NEW YORK (GenomeWeb News) – Third Wave Technologies said today that revenues for the second quarter increased approximately 17 percent, including an 18-percent spike in clinical molecular diagnostic receipts, as net losses declined.
Third Wave said revenue for the three months ended June 30 increased to $6.8 million from $5.8 million year over year. The company reported $5.1 million in clinical molecular diagnostic revenues and $1.6 million in research revenues.
Net loss for the second quarter declined to $4.7 million from $5.5 million in the same quarter one year ago.
R&D spending in the period increased to about $3 million from $2 million in the year-ago period.
As of June 30, Third Wave had $36.2 million in cash, cash equivalents, and short-term investments.
In addition, Third Wave said it would launch its Universal Invader Plus program earlier than anticipated as customer evaluations have progressed.

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.